Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Russano has a total of 124 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Photoimmunotherapy Meets Systemic Immunotherapy: Molecular Mechanisms, Microenvironmental Remodeling, and Combinatorial Paradigms in Solid Tumors

    by Francesco Russano, Francesco Callegarin, Davide Brugnolo, Marco Rastrelli, Rocco Caminiti, Giuseppe Sciacca, Daniele Scafuri, Marcodomenico Mazza, Paolo Del Fiore, Luigi Dall’Olmo, et al.

    Photodynamic therapy (PDT) remains constrained by physical barriers, including strict oxygen dependence, acute hypoxia exacerbation, and limited light penetration depth. While conventional photodynamic therapy (PDT) is strictly oxygen-dependent and limited by light scattering, Near-Infrared Photoimmunotherapy (NIR-PIT) overcomes microenvironmental hypoxia through targeted, oxygen-independent biophysical membrane rupture. However, tissue optical attenuation at 690 nm remains a fundamental physical boundary that necessitates interstitial fiber placement for deep lesions. Concurrently, recent advances in bioengineered nano-photoimmunotherapy (nano-PIT) and organelle-targeted photodynamic/photothermal platforms deliberately execute alternative inflammatory non-apoptotic pathways, such as pyroptosis, cuproptosis, and ferroptosis, and provoke cytosolic leakage of mitochondrial DNA that engages the cGAS-STING innate immune axis. Concurrently, NIR-PIT comprehensively remodels the immunosuppressive tumor microenvironment (TME) by selectively depleting regulatory T cells (Tregs), myeloid-derived suppressor (MDSCs) cells, and cancer-associated fibroblasts (CAFs), thereby deconstructing desmoplastic stroma, lowering interstitial fluid pressure (IFP), and driving the Super-Enhanced Permeability and Retention (SUPR) effect. Photically released mitochondrial DNA further engages the cytosolic cGAS-STING pathway, stimulating type I interferon signaling and dendritic cell cross-presentation. In selected preclinical models, this biophysical collapse promotes immunogenic cell death (ICD) and tumor microenvironment remodeling. When combined with systemic immunotherapies, NIR-PIT has demonstrated the potential to prime antitumor immunity and elicit abscopal responses in responsive syngeneic models; however, this immune conversion is not universal and is heavily constrained by tumor mutational burden, baseline antigen presentation fidelity, and diverse immunosuppressive networks. Translating these paradigms into clinical practice requires advancing 3D microphysiological models, implantable light technologies, and multi-component dosimetry frameworks.

  • Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial

    by Axel Hauschild, Jessica Cecile Hassel, Mirjana Ziemer, Piotr Rutkowski, Friedegund Meier, Lukas Flatz, Caroline Gaudy-Marqueste, Mario Santinami, Francesco Russano, Imke von Wasielewski, et al.

    Daromun (L19IL2/L19TNF) was investigated as a neoadjuvant, intralesional therapy for patients with fully resectable stage III melanoma in the phase III PIVOTAL trial (ClinicalTrials.gov identifier: NCT02938299 ). The trial enrolled 256 patients in the European Union and met its primary end point, demonstrating a statistically significant improvement in recurrence-free survival (RFS; hazard ratio, 0.59; P = .005) for daromun followed by surgery versus up-front surgery, at a median follow-up (FU) of 21 months from random assignment. PIVOTAL included two clinically distinct subgroups, namely, patients with de novo diagnosed metastatic disease (n = 34; 13%) and patients with recurrence(s) after surgery with or without radiotherapy and/or adjuvant systemic therapies (n = 222; 87%). Here, we present an updated analysis of the primary and secondary end points, including safety data, at a median FU of 36.8 months from random assignment (database cutoff: November 28, 2025), alongside new sensitivity analyses of event-free survival (EFS). The updated analysis confirms the clinically and statistically meaningful improvements in RFS and distant metastasis-free survival recorded in the neoadjuvant daromun versus control arm. The EFS post hoc analysis, conducted in both the overall population and the recurrent patient subgroups (with or without prior systemic therapies), provides consistency and robustness to the benefit of neoadjuvant daromun observed for the primary efficacy end point. No new safety signals of concern were recorded.


  • Open Access

    Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy

    by Francesco Russano, Luigi Dall’Olmo, Davide Brugnolo, Francesco Callegarin, Marcodomenico Mazza, Paolo Del Fiore, Rocco Caminiti, Marco Rastrelli, Simone Mocellin

    Malignant melanoma presents formidable therapeutic challenges due to optical shielding and free-radical scavenging by endogenous melanin, profound tumor microenvironment hypoxia, and aggressive metastatic dissemination, rendering conventional photodynamic therapy (PDT) clinically immature. This narrative review comprehensively synthesizes literature across PubMed/MEDLINE, Scopus, and Web of Science evaluating photochemical mechanisms, photosensitizing agents, bioengineered drug delivery systems, and adjacent light-triggered strategies. Preclinical evidence demonstrates that third-generation photosensitizers, targeted organic/inorganic nanoparticles, and transdermal dissolving microneedle (MN) arrays effectively bypass the stratum corneum, enhance drug bioavailability, and alleviate hypoxia-mediated treatment resistance. Furthermore, femtosecond two-photon PDT converts melanin into an active energy-transfer mediator, while nanotechnology-driven photoimmunotherapy (PIT) triggers immunogenic cell death (ICD) and systemic CD8+ cytotoxic T-lymphocyte activation to induce abscopal regression of un-irradiated distant metastases. Nevertheless, critical translational bottlenecks persist, including an overwhelming reliance on static two-dimensional (2D) cell cultures, a lack of validated prognostic or predictive biomarkers, and a complete absence of randomized controlled clinical trials. Ultimately, advancing melanoma photomedicine from bench to bedside requires standardized photophysical dosimetry, systematic evaluation in multicellular three-dimensional (3D) tumor spheroids, and prospective clinical trials defining its role in multimodal dermato-oncology.

  • Open Access

    Severe Refractory Hypotension Following Patent Blue V Injection: A Case of Atypical Perioperative Anaphylaxis

    by Francesco Russano, Vittoria Patti, Cinzia Bettin, Massimiliano Caravello, Davide Brugnolo, Paolo Del Fiore

    Background and Clinical Significance: Patent Blue V (PBV) is widely used for sentinel lymph node mapping but may rarely cause severe hypersensitivity reactions. These reactions can present atypically, with predominant cardiovascular collapse and minimal cutaneous manifestations, potentially delaying recognition and treatment. Case Presentation: We report the case of a 52-year-old woman who developed sudden and prolonged refractory hypotension shortly after PBV injection during melanoma surgery. The reaction initially occurred in the absence of bronchospasm or early significant cutaneous manifestations. Profound cardiovascular collapse preceded the delayed appearance of erythema and piloerection, making early recognition of perioperative anaphylaxis particularly challenging. Hemodynamic instability required aggressive fluid resuscitation and prolonged vasopressor support. Subsequent diagnostic work-up, including serum tryptase measurement and allergological evaluation, confirmed PBV-induced anaphylaxis. PBV-induced anaphylaxis may present with isolated cardiovascular collapse without typical clinical features. Conclusions: Early recognition and prompt hemodynamic support are essential to optimize outcomes in the perioperative setting.


  • Open Access

    Photodynamic Therapy for Keratinocytic Precancerous Lesions and Non-Melanoma Skin Cancer: A Narrative Review

    by Francesco Russano, Luigi Dall’Olmo, Davide Brugnolo, Francesco Callegarin, Paolo Del Fiore, Rocco Caminiti, Marco Rastrelli, Simone Mocellin

    Photodynamic therapy (PDT) is a cornerstone non-invasive modality for keratinocytic precancers and non-melanoma skin cancer (NMSC), leveraging selective photosensitizer accumulation, light activation, and reactive oxygen species (ROS) generation. This narrative review synthesized literature from major databases (2010–2025) to comprehensively evaluate PDT’s molecular mechanisms, innovative optimization protocols, and clinical efficacy across actinic keratosis (AK), field cancerization, Bowen’s disease (BD), basal cell carcinoma (BCC), and invasive squamous cell carcinoma (cSCC). The evidence highlights frontline clinical maturity and excellent cosmetic outcomes for superficial lesions (AK, field cancerization, superficial BCC, and BD), with daylight PDT offering a virtually painless alternative for widespread dysplasia. However, therapeutic reliability decreases in thick nodular, pigmented, or high-risk lesions due to optical barriers and tissue hypoxia. To overcome these limitations, advanced physical and chemical enhancements—such as ablative fractional lasers, iron chelators, epigenetically enhanced PDT (ePDT), and targeted nanocarriers—are actively reshaping drug delivery and cellular susceptibility. Furthermore, cyclic PDT serves as an indispensable tissue-sparing intervention for organ transplant recipients and Gorlin syndrome patients. In conclusion, while PDT is highly effective for superficial neoplasias, precise histopathological stratification and the integration of nanomedicine are critical to overcoming current biological barriers in aggressive dermatological malignancies.

  • Open Access

    The Role of Laser Modalities in Melanoma Management: Critical Analysis of Local Control and Palliative Applications

    by Francesco Russano, Luigi Dall’Olmo, Francesco Callegarin, Davide Brugnolo, Paolo Del Fiore, Giuseppe Sciacca, Rocco Caminiti, Marco Rastrelli, Simone Mocellin

    Cutaneous melanoma is an aggressive skin cancer. While laser therapy is established for non-melanoma skin cancers, its role in melanoma remains controversial and largely unsupported by robust clinical evidence. The gold standard for melanoma management remains surgical excision, as it allows for definitive histopathological diagnosis, Breslow thickness measurement, and surgical margin assessment, which are essential for accurate staging. This narrative review analyzed preclinical and clinical studies evaluating various laser modalities, including Nd:YAG, CO2, pulsed dye, photodynamic therapy (PDT) and photothermal therapy (PTT), for efficacy, recurrence rates, and limitations in cutaneous melanoma management. Nd:YAG laser (1064 nm) showed potential for local control in thin stage I melanomas, reporting a low local recurrence rate of 0–0.7% and favorable 5-year survival in small, non-randomized cohorts. CO2 laser (10,600 nm) provides effective palliation and local control for in-transit or unresectable metastases, but local recurrence is highly variable, reaching up to 46.7%. Photodynamic therapy showed variable efficacy, although Chlorin e6 achieved complete local regression in a small series of metastases. A critical limitation of laser therapy is the irreversible destruction of tissue, which precludes these vital assessments. Therefore, laser treatment should be cautiously reserved for cases where standard surgery is not feasible, acknowledging that it may interfere with the evaluation of curative outcomes and accurate staging. Laser therapy is a valuable minimally invasive adjunct for local control in selected patients who are poor surgical candidates or require palliative care. Routine use is restricted by the lack of randomized controlled trials. Future studies should prioritize combination strategies with systemic or immunotherapeutic approaches to enhance overall outcomes.

  • Open Access

    MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials

    by Francesco Russano, Mattia Sturlese, Luigi Dall’olmo, Francesco Callegarin, Davide Brugnolo, Paolo Del Fiore, Vittoria Patti, Arianna Purpura, Stefano Moro, Marco Rastrelli, et al.

    The Murine Double Minute 2 (MDM2) gene encodes an E3 ubiquitin ligase that negatively regulates the tumor suppressor p53, maintaining low p53 levels through ubiquitination and proteasomal degradation. MDM2 overexpression in various malignancies leads to reduced p53 activity, contributing to tumor initiation and resistance to therapies. As such, MDM2 is a promising target for drug development. Innovative small-molecule inhibitors are being designed to disrupt the MDM2-p53 interaction, thereby restoring p53’s tumor-suppressive functions. This review focuses on clinical trials evaluating MDM2 inhibition for cancer therapy. MDM2 exerts its oncogenic effects primarily through its interaction with p53 but also has p53-independent functions involved in cell cycle progression and DNA repair. Elevated MDM2 expression is associated with poor prognosis across various cancers, including dedifferentiated liposarcoma, breast cancer, and glioblastoma. Targeting MDM2 with inhibitors has shown promising potential in clinical development, aiming to reactivate p53’s functions in tumors with wild-type TP53, improving therapeutic outcomes in cancer treatment.


  • Open Access

    The Safety of Negative-Pressure Wound Therapy in Melanoma and Sarcoma Patients: A Systematic Review

    by Silvia Dal Pos, Stela Tafaj, Ilda Hoxhaj, Fortunato Cassalia, Francesco Russano, Saveria Tropea, Paolo Del Fiore, Marcodomenico Mazza

    Background/Objectives: Negative-Pressure Wound Therapy (NPWT) is increasingly used to promote wound healing in chronic and complicated wounds, but its use in surgical oncology is still debated due to theoretical concerns about promoting local tumor recurrence. The aim of this study is to review the available evidence on the oncologic safety of NPWT, specifically regarding the risk of local recurrence in patients undergoing surgery for cutaneous melanoma (CM) or soft tissue sarcoma (STS). Methods: A systematic review of the literature was conducted using the MEDLINE/PubMed, EMBASE, and Scopus databases through December 2024 (PROSPERO: CRD42024623405). Case series, retrospective cohort studies, and randomized clinical trials reporting survival data in melanoma and sarcoma patients treated with NPWT were eligible for inclusion. PRISMA guidelines were followed and quality assessment checked. Results: Seventeen studies were eligible for the analysis with a total of 285 patients, 197 affected by soft tissue sarcoma and 88 by cutaneous melanoma. The pooled proportion of local recurrence was 5% in patients treated with NPWT, regardless of the histology considered (STS and CM). When comparing NPWT to conventional wound therapy, both the pooled risk ratio (0.87; 95% CI: 0.24–3.11; Tau2 = 0.14; I2 = 8%) and odds ratio (0.83; 95% CI: 0.20–3.39; Tau2 = 0.18) indicated no statistically significant difference in the recurrence rate. Conclusions: Current evidence does not suggest an increased risk of local recurrence associated with NPWT in melanoma or sarcoma patients, and mostly, NPWT may have important advantages over standard surgical dressings. More high-power randomized controlled trials with wider follow-up periods are needed to make it possible for practitioners to use this technique without being afraid of higher risk local recurrences.

  • Open Access

    The Role of Electrochemotherapy in Managing Cutaneous Metastases from Breast Carcinoma: A Narrative Review

    by Francesco Russano, Davide Brugnolo, Paolo Del Fiore, Marco Rastrelli, Luigi Dall’olmo, Simone Mocellin

    Cutaneous metastases from breast carcinoma represent a debilitating complication of advanced disease progression, significantly impacting patients’ quality of life. Electrochemotherapy (ECT), which combines cytotoxic drugs such as bleomycin or cisplatin with electric pulses to enhance cellular permeability, has shown promising efficacy as a local treatment for these lesions. Objectives: This literature review examines the principles of ECT, its mechanisms of action and the clinical outcomes in patients with primary breast cancer. Across clinical series, patient-level ORR typically ranges from ~70–90% and CR up to ~58% at 6–12 weeks, with lower rates in larger (>3 cm) or deeper lesions. ECT is safe, well tolerated, and potentially synergistic with other systemic therapies. However, its efficacy is influenced by factors such as lesion size, tumor receptor status, and prior radiotherapy. Optimizing patient selection, standardizing treatment protocols, and developing combination approaches with immunotherapy or targeted therapies represent key future directions to improve clinical outcomes.


  • Electrochemotherapy for cutaneous Kaposi Sarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT)

    by Pietro Quaglino, Matteo Brizio, Giulia Bertino, Erika Kis, Matteo Mascherini, Michela Battista, Christian Kunte, David Mowatt, Francesco Russano, Roberto Giorgione, et al.